Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
7(87.5%)
Phase 3
1(12.5%)
8Total
Phase 1(7)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT04495296Phase 1Recruiting

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Role: lead

NCT04396821Phase 1Active Not Recruiting

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Role: lead

NCT06093425Phase 3Not Yet Recruiting

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Role: lead

NCT05731271Phase 1Active Not Recruiting

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Role: lead

NCT06716788Not Yet Recruiting

68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy

Role: collaborator

NCT04272944Phase 1Completed

A Study of MSB2311 in Advanced Solid Tumors

Role: lead

NCT03463473Phase 1Completed

A Phase I Study of MSB2311 in Advanced Solid Tumors

Role: lead

NCT04958434Phase 1Terminated

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT04381325Phase 1Terminated

A Study of MSB0254 Injection in Advanced Solid Tumors

Role: lead

All 9 trials loaded